Serum Estradiol Level and Risk of Breast Cancer During Treatment With Raloxifene
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
CONTEXT: As endogenous estradiol increases, risk of breast cancer increases. Raloxifene competes with endogenous estrogen for binding to estrogen receptors in breast tissue. A woman's estradiol level may alter the effects of raloxifene on breast cancer and other outcomes. OBJECTIVE: To test the hypothesis that raloxifene reduces breast cancer risk more in women with relatively high estradiol levels than in women with very low estradiol levels. DESIGN: Analysis of the Multiple Outcomes of Raloxifene Evaluation, a randomized, double-blind, placebo-controlled trial conducted from 1994 to 1999. SETTING: One hundred eighty community settings and medical practices in 25 countries including the United States. PARTICIPANTS: A total of 7290 postmenopausal women aged 80 years or younger with osteoporosis who had baseline serum estradiol concentrations measured by a central laboratory using a sensitive assay. Women with a history of breast cancer or estrogen use were excluded. INTERVENTION: Participants were randomly assigned to receive 60 mg/d or 120 mg/d of raloxifene (n = 4843) or matching placebo (n = 2447) for 4 years. MAIN OUTCOME MEASURE: New cases of histopathologically confirmed breast cancer in the treatment and placebo groups, stratified by estradiol levels. RESULTS: In the placebo group, women with estradiol levels greater than 10 pmol/L (2.7 pg/mL) had a 6.8-fold higher rate of breast cancer (3.0% per 4 years; 95% confidence interval [CI], 1.8%-4.1%) than that of women with undetectable estradiol levels (0.6% per 4 years; 95% CI, 0%-1.1%; P =.005 for trend). Women with estradiol levels greater than 10 pmol/L in the raloxifene group had a rate of breast cancer that was 76% (95% CI, 53%-88%) lower than that of women with estradiol levels greater than 10 pmol/L in the placebo group (absolute rate reduction, 2.2% [95% CI, 1.0%-3.5%; number needed to treat = 45]). In contrast, women with undetectable estradiol levels had similar breast cancer risk whether or not they were treated with raloxifene (risk difference, -0.1%; 95% CI, -0.8% to 0.6%; P =.02 for the interaction). In this cohort, treating women with estradiol levels greater than 10 pmol/L with raloxifene for 4 years would have avoided 47% of breast cancer cases. CONCLUSIONS: Measurement of estradiol level by sensitive assay in postmenopausal women identifies those at high risk of breast cancer who may benefit most from raloxifene. If confirmed, this suggests that measuring estradiol and treating women with high estradiol levels could substantially reduce the rate of breast cancer among postmenopausal women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., & Mulvihill, J. J. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1879 · Cited by 3,334
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Self-citationCauley, J. A., Lucas, F. L., Kuller, L. H., Stone, K., Browner, W., Cummings, S. R., & for the Study of Osteoporotic Fractures Research Group (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-4_part_1-199902160-00004 · Cited by 409
Self-citation
Cited by
Winer, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,031
Paruthiyil, S., Parmar, H., Kerekatte, V., Cunha, G. R., Firestone, G. L., & Leitman, D. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2446 · Cited by 576
The Role of Prolactin in Mammary Carcinoma
Clevenger, C. V., Furth, P. A., Hankinson, S. E., & Schuler, L. A. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0036 · Cited by 545
Missmer, S. A., Eliassen, A. H., Barbieri, R. L., & Hankinson, S. E. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh336 · Cited by 516
Quantitative Assessment of Mammographic Breast Density: Relationship with Breast Cancer Risk
Harvey, J. A., & Bovbjerg, V. E. (2004) · Radiology · doi:10.1148/radiol.2301020870 · Cited by 491
Nelson, R. E., Grebe, S. K., O’Kane, D. J., & Singh, R. J. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.025478 · Cited by 359
Hankinson, S. E., Colditz, G. A., & Willett, W. C. (2004) · Breast Cancer Research · doi:10.1186/bcr921 · Cited by 270
Prevention of Breast Cancer in Postmenopausal Women: Approaches to Estimating and Reducing Risk
Cummings, S. R., Tice, J. A., Bauer, S., Browner, W. S., Cuzick, J., Ziv, E., Vogel, V., Shepherd, J., Vachon, C., Smith-Bindman, R., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp018 · Cited by 254
Self-citationWiner, E. P., Hudis, C., Burstein, H. J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gralow, J., Goldstein, L. J., Pritchard, K. I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.020 · Cited by 200
Mosquera, L., Colón, J. M., Santiago, J. M., Torrado, A. I., Meléndez, M., Segarra, A. C., Rodríguez-Orengo, J. F., & Miranda, J. D. (2014) · Brain Research · doi:10.1016/j.brainres.2014.03.002 · Cited by 74
“…could be valuable in SCI as well as Alzheimer, Parkinson, TBI, and ischemic strokes, long-term therapy may be associated with an increased risk of cancer, deep vein thrombosis or pulmonary embolism (Breckwoldt and Karck, 2000; Cummings et al., 2002; Laliberté et al., 2011; Sare et al., 2008).”
Gibney, J., Johannsson, G., Leung, K.-C., & Ho, K. K. Y. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0173 · Cited by 40
Metadata
- Authors
- Cummings, S. R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2002-01-09
- Volume
- 287
- Issue
- 2
- Pages
- 216
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2116459270
- Cited by
- 219
- References
- 4
- FWCI
- 14.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.